The strong growth in the domestic arena, led by focus on specialty and covid treatment drugs, has kept investor interest firm. The respiratory drug portfolio in the US, and the growth associated with it are also supporting Street confidence. Covid treatments drugs, including remdesivir, have kept the company’s India sales growth strong. The launch of Albuterol inhaler generics has helped the company’s sales momentum catch pace in the US during FY21. Analysts now eye the approval of Advair inhaler generics in the US which is expected to help Cipla sales gain further momentum.

Source: Mint July 09, 2021 06:11 UTC